On July 13, 2022 EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry with its Asian regional headquarters in Singapore and offices across Japan, China and other countries in the area, and Compai Pharma, an enterprising pharmaceutical company offering full-service commercialisation with offices in Singapore and Malaysia, reported a strategic partnership to expand service across the Asia Pacific region (Press release, EVERSANA, JUL 13, 2022, View Source [SID1234616608]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Together, EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners to support full market implementation and development for life science and pharmaceutical companies ready to expand into these markets.

"As the needs of clients and their patients continue to grow, so too do our capabilities to scale delivery on a global level," said Jim Lang, CEO, EVERSANA. "The Asia Pacific region is one of the fastest-growing pharmaceutical markets in the world and requires regional expertise to increase patient access. Together with Compai Pharma, we’re now able to drive greater value and services for our clients to support their evolving commercialisation needs."

Capabilities available through the partnership include consulting, market access, medical awareness, education and communication, pharmacovigilance, marketing & sales excellence, as well as distribution and additional services.

"I am deeply honoured and excited to enter this partnership with such an esteemed company as EVERSANA," said Tim Cushway, Founder and Director at Compai Pharma. "Our mission is to work closely with healthcare practitioners across APAC to ensure needed medications and devices are available for patients while also becoming a trusted partner to provide education and updates on the latest in clinical developments. This goal is highly synergistic with EVERSANA’s global ambition."

The partnership with Compai builds on EVERSANA’s continued global growth, including recent expansion across the European Union and the United Kingdom. Additionally in June 2021, EVERSANA announced the growth of its medical communications and integrated compliance services across 18 European countries and in 10 local languages.

On July 12, 2022 Tailor Bio reported it has received a £650,000 grant through the Innovate UK Biomedical Catalyst Award in support of its ambitions to develop a pan-cancer precision medicine platform (Press release, Tailor Bio, JUL 12, 2022, View Source [SID1234641526]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tailor will use the funds to develop its first diagnostic to identify which high-grade serous ovarian cancer patients will not respond to doxorubicin chemotherapy. In the UK, 7,000 women are diagnosed with ovarian cancer each year, and only half will respond to doxorubicin, a commonly prescribed treatment.

The startup will collaborate with Illumina and the University of Cambridge on developing the diagnostic. The partners will also assess the compatibility of Tailor’s platform with the Illumina TruSight Oncology Comprehensive assay, which now has CE-IVD marking in Europe.

"In addition to addressing an unmet need in ovarian cancer, Tailor’s doxorubicin test is a pivotal step for us to validate our precision medicine platform," Tailor CEO Jason Yip said in a statement. "Stratifying patients away from ineffective treatment is beneficial, but the ultimate aim of Tailor Bio is to develop better therapeutic treatments for cancers with chromosomal instability."

The science underlying Tailor’s commercial ambitions originated at the Cancer Research UK (CRUK) Cambridge Institute and the Spanish National Cancer Research Centre (CNIO). In June, research led by two Tailor Bio executives and published in Nature explored copy number signatures that coincide with chromosomal instability as potential prognostic and predictive biomarkers for cancer. Based on that research, the authors established Tailor Bio to further validate these biomarkers and bring them to the clinic.

Tailor Bio launched in 2020 out of the Illumina Accelerator program, which provides seed funding, access to Illumina platforms, business and scientific expertise, and access to lab space.

On July 12, 2022 Alligator Bioscience reported interim report January to June 2022 (Presentation, Alligator Bioscience, JUL 12, 2022, View Source [SID1234618929]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 12, 2022 Oncotelic Therapeutics, Inc. (the "Company"), presented the Corporate Presentation (Presentation, Mateon Therapeutics, JUL 12, 2022, View Source [SID1234616702]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 12, 2022 Neuraxpharm Group ("Neuraxpharm") reported that it has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases from Sanofi (Press release, Sanofi, JUL 12, 2022, View Source [SID1234616635]). With the upcoming acquisition, Neuraxpharm will strengthen its position as a leading European specialty pharmaceutical company focused on CNS. The well-established products that Neuraxpharm will acquire are marketed globally in more than 50 countries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first portfolio combines 15 products addressing CNS disorders and ranging across psychiatry and neurology. The second portfolio includes two products in pain and vascular diseases. Following the acquisition of these new portfolios, Neuraxpharm’s annual gross sales will be around EUR 0.6 billion.

The products benefit patients across a large spectrum of diseases including depression, anxiety, psychosis, alcohol dependence, myasthenia gravis and Parkinson disease. The CNS portfolio notably includes Nozinan, Tranxene, Tiapridal, Dogmatil, Largactil. The pain and vascular portfolio includes Topalgic and Trental.

Combined, both portfolios include 17 molecules representing 38 brands. These global brands will further solidify Neuraxpharm’s position as a leading CNS pharmaceutical company in Europe and increase the company’s global footprint and business.

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: "There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven by an ageing population and an increasing awareness of mental health. This phenomenon is a global trend. With the upcoming acquisition, we will not only strengthen our presence in Europe, but also lay the ground for further expanding our international presence."